{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T19:04:35Z","timestamp":1759777475912,"version":"3.32.0"},"reference-count":49,"publisher":"Informa UK Limited","issue":"1","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Pharmacotherapy"],"published-print":{"date-parts":[[2025,1,2]]},"DOI":"10.1080\/14656566.2024.2436593","type":"journal-article","created":{"date-parts":[[2024,12,4]],"date-time":"2024-12-04T12:45:32Z","timestamp":1733316332000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Evaluating semaglutide + LAI-287 (IcoSema) for the treatment of diabetes mellitus type II"],"prefix":"10.1080","volume":"26","author":[{"given":"Maka","family":"Siamashvili","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen N.","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2024,12,4]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc23-S002"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.621416"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.29.3.116"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2006.00686.x"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmsa2032271"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000654"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.2337\/dcS15-3011"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005613.pub4"},{"key":"e_1_3_4_10_1","unstructured":"Novo Nordisk Global. Novo nordisk receives complete response letter in the US for once-weekly basal insulin icodec [Internet]. [cited 2024 Jul 11]. Available from: https:\/\/www.novonordisk.com\/news-and-media\/news-and-ir-materials\/news-details.html?id=168532#"},{"key":"e_1_3_4_11_1","unstructured":"Novo Nordisk. Insulin icodec treatment to improve glycemic control in adults with diabetes mellitus [Internet]. [cited 2024 Jul 11]. Available from: https:\/\/www.fda.gov\/media\/178822\/download"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc24-SDIS"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12839"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13300-018-0424-2"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-022-00726-z"},{"key":"e_1_3_4_16_1","unstructured":"Novo Nordisk Global. COMBINE 3 phase 3a trial successfully completed with once-weekly IcoSema demonstrating non-inferior reduction in HbA1c versus daily basal-bolus treatment (insulin glargine U100 and insulin aspart) in people with type 2 diabetes [Internet]. [cited 2024 Jul 11]. Available from: https:\/\/www.novonordisk.com\/content\/nncorp\/global\/en\/news-and-media\/news-and-ir-materials\/news-details.html?id=167008"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.1c00257"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b00726"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15266"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-022-01243-6"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-024-01375-2"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.03.020"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-018-0668-z"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1131"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0528-2"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-017-0532-6"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.443"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30013-X"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30092-X"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(17)30085-2"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2018-00070"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(18)30024-X"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.2337\/dc17-0417"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1607141"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14871"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2303208"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00093-1"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.11313"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00520-2"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23-1288"},{"key":"e_1_3_4_41_1","unstructured":"ClinicalTrials.gov. A research study to see how well the new weekly medicine IcoSema which is a combination of insulin icodec and semaglutide controls blood sugar level in people with type 2 diabetes compared to weekly semaglutide (COMBINE 2) [Internet]. [cited 2024 Jul 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05259033?intr=icosema&rank=3"},{"key":"e_1_3_4_42_1","unstructured":"ClinicalTrials.gov. A research study to see how well the new weekly medicine IcoSema which is a combination of insulin icodec and semaglutide controls blood sugar level in people with type 2 diabetes compared to insulin glargine taken daily with insulin aspart (COMBINE 3) [Internet]. [cited 2024 Jul 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05013229?intr=icosema&rank=5"},{"key":"e_1_3_4_43_1","unstructured":"ClinicalTrials.gov. A research study to see how well new weekly medicine IcoSema which is a combination of insulin icodec and semaglutide controls blood sugar levels in people with type 2 diabetes (T2D) compared to daily insulin glargine (COMBINE 4) [Internet]. [cited 2024 Jul 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06269107?intr=icosema&rank=1"},{"key":"e_1_3_4_44_1","unstructured":"ClinicalTrials.gov. A research study to look at how insulin icodec and semaglutide work in the body of people from China with type 2 diabetes when given alone or together [Internet]. [cited 2024 Jul 13]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05435677?intr=icosema&rank=4&tab=table"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.12.001"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.2337\/diaspect.29.3.166"},{"key":"e_1_3_4_47_1","unstructured":"Wexler D. Insulin therapy in type 2 diabetes mellitus. UpToDate [Internet]. [cited 2024 Jul 13]."},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2021-002396"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac150.590"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1111\/dom.13361"}],"container-title":["Expert Opinion on Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14656566.2024.2436593","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T14:33:30Z","timestamp":1735742010000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14656566.2024.2436593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,4]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,2]]}},"alternative-id":["10.1080\/14656566.2024.2436593"],"URL":"https:\/\/doi.org\/10.1080\/14656566.2024.2436593","relation":{},"ISSN":["1465-6566","1744-7666"],"issn-type":[{"type":"print","value":"1465-6566"},{"type":"electronic","value":"1744-7666"}],"subject":[],"published":{"date-parts":[[2024,12,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieop20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-11-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}